Expression of the transcription factor cKrox in peripheral CD8 T cells reveals substantial postthymic plasticity in CD4-CD8 lineage differentiation by Jenkinson, S. Rhiannon et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
BRIEF DEFINITIVE REPORT
Vol. 204, No. 2,  February 19, 2007  267–272  www.jem.org/cgi/doi/10.1084/jem.20061982 267
An emerging concept is that cell diff  erentiation 
is maintained at least in part by inheritable 
changes in DNA or chromatin organization, 
referred to as epigenetic modifi  cations (1). In 
the lymphoid system, epigenetic control of 
gene expression is epitomized by the perpetua-
tion of CD4 silencing in postthymic CD8 
T cells independently from the genetic ele-
ments needed to establish silencing in diff  eren-
tiating CD8 thymocytes (2–5). CD8 T cells are 
restricted by MHC I molecules and possess 
cytotoxic activity by direct target cell lysis or 
through secretion of IFN-γ (6). In contrast, 
CD4 cells, which are MHC II restricted, gen-
erally provide help to other immune cells 
through cytokine secretion and expression of 
specifi  c surface molecules. Because epigenetic 
marking aff   ects the expression of multiple 
lineage-specifi   c genes in mature T cells, in-
cluding CD4, CD8, and type 2 eff  ector cyto-
kines such as IL-4 (1, 7–9), it is conceivable 
that such mechanisms lock CD4-CD8 lineage 
diff   erentiation after exit from the thymus. 
A direct correlate of this hypothesis is that 
CD4-CD8 diff  erentiation in mature T cells 
should no longer be aff  ected by the transcrip-
tion factors that direct lineage choice in thy-
mocytes. Because the nuclear eff  ectors  that 
direct lineage choice during positive selection 
in the thymus were unknown, this prediction 
remains to be evaluated.
The zinc fi  nger transcription factor cKrox 
(also called Zbtb7b or Thpok) is a master switch 
of CD4 diff   erentiation. It is induced during 
MHC II–induced positive selection, promotes 
CD4 and helper diff  erentiation (10, 11), and 
is necessary for CD4 T cell generation (10). 
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Most T cells belong to either of two lineages defi  ned by the mutually exclusive expression 
of CD4 and CD8 coreceptors: CD4 T cells are major histocompatibility complex (MHC) II 
restricted and have helper function, whereas CD8 T cells are MHC I restricted and have 
cytotoxic function. The divergence between these two lineages occurs during intrathymic 
selection and is thought to be irreversible in mature T cells. It is, however, unclear whether 
the CD4-CD8 differentiation of postthymic T cells retains some level of plasticity or is 
stably maintained by mechanisms distinct from those that set lineage choice in the thymus. 
To address this issue, we examined if coreceptor or effector gene expression in mature CD8 
T cells remains sensitive to the zinc fi  nger transcription factor cKrox, which promotes CD4 
and inhibits CD8 differentiation when expressed in thymocytes. We show that cKrox trans-
duction into CD8 T cells inhibits their expression of CD8 and cytotoxic effector genes and 
impairs their cytotoxic activity, and that it promotes expression of helper-specifi  c genes, 
although not of CD4 itself. These observations reveal a persistent degree of plasticity in 
CD4-CD8 differentiation in mature T cells.
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Here, we exploited these fi  ndings to evaluate how “plastic” 
lineage-specifi  c gene expression remained in postthymic 
T cells. We found that introducing cKrox into CD8 T cells, 
in which it is normally not expressed, inhibited their expres-
sion of CD8 coreceptor and cytotoxic eff  ector genes, and 
up-regulated genes characteristic of helper diff  erentiation, 
although not of CD4 itself. These fi  ndings reveal a substantial 
plasticity in the CD4-CD8 lineage diff  erentiation of mature 
T cells.
RESULTS AND DISCUSSION
To evaluate the “plasticity” of CD4-CD8 diff  erentiation in 
postthymic T cells, we used a GFP-based retrovirus (Fig. S1 A, 
available at http://www.jem.org/cgi/content/full/jem
.20061982/DC1) to introduce cKrox into CD8 cells, in 
which it is normally not expressed. Immunoblot analyses de-
tected the cKrox protein in GFP+ CD8 T cells transduced by 
the cKrox vector but not in GFP+ cells transduced with a 
control vector lacking the cKrox insert (Fig. S1 B).
We fi   rst assessed the eff   ect of cKrox on coreceptor 
expression. Although cKrox-transduced CD8 T cells did not 
reexpress CD4, their CD8 expression was reduced compared 
with nontransduced or control-transduced cells (Fig. 1 A). 
To examine if this eff  ect was transcriptional, we evaluated if 
cKrox aff   ected the activity of the E8(I) CD8 enhancer 
element, unique among the fi  ve known CD8 enhancers for 
being active in mature CD8 T cells only (2, 9, 12, 13). Mice 
carrying an E8(I)-driven human CD2 (hCD2) cDNA trans-
gene expressed the hCD2 reporter in CD8 T cells but not in 
double positive thymocytes or CD4 T cells (13 and not de-
picted). Retroviral transduction of cKrox in E8(I)-hCD2 
transgenic CD8 T cells markedly reduced hCD2 expression 
(Fig. 1 B), demonstrating that cKrox-mediated CD8 repres-
sion is transcriptional. These observations identify E8(I) as a 
direct or indirect target of cKrox.
The repression of E8(I) by cKrox was dose dependent, as 
cells with high cKrox expression (assessed from GFP levels) 
failed to express hCD2 (Fig. 1 B). In contrast, the repression 
of endogenous CD8 expression by cKrox was not as clearly 
dose dependent, as CD8 levels were broadly distributed on 
GFPhi cKrox-transduced cells (Fig. 1 A). It is possible that 
additional CD8 enhancers are not repressed by cKrox, or not 
as strongly as E8(I). However, a more intriguing possibility is 
that the broad distribution of CD8 levels on GFPhi cKrox-
transduced cells is caused by variegation, a pattern typical of 
epigenetic silencing (9), raising the possibility that epigenetic 
silencing of CD8 is initiated in postthymic cells as a conse-
quence of repression by cKrox.
cKrox impairs expression of cytotoxic genes 
in peripheral CD8 T cells
That cKrox impaired CD8 expression in postthymic T cells 
prompted us to examine whether cKrox would repress cyto-
toxic eff  ector genes normally expressed in CD8 but not CD4 
cells (14). Real-time PCR amplifi  cation of reverse-transcribed 
cDNAs (RT-PCR) showed that cKrox transduction reduced 
the expression of genes encoding the cytotoxic eff  ectors per-
forin and granzyme B (Fig. 2 A). Flow cytometric analyses 
confi  rmed that cKrox impaired granzyme B protein expres-
sion (Fig. 2 B). In agreement with these fi  ndings, transduction 
of cKrox in mature CD8 T cells carrying the Db-restricted 
P14 TCR transgene impaired their ability to lyse targets 
cells loaded with their cognate lymphocytic choriomeningitis 
virus (LCMV) gp33 peptide (Fig. 2 C and Figs. S2 and S3, 
which are available at http://www.jem.org/cgi/content/full/
jem.20061982/DC1).
We next examined whether cKrox transduction aff  ected 
production of IFN-γ, a cytokine produced at high levels by 
CD8 T cells (14). These experiments were performed on 
cells activated in type 2 conditions that are permissive to 
IFN-γ production by CD8 but not by CD4 T cells. cKrox 
reduced CD8 cell expression of IFN-γ both at the mRNA 
and protein levels (Fig. 2, A and D). This eff  ect was cell 
autonomous, as IFN-γ production was not reduced in 
  un  infected (GFP−) CD8 cells in the same culture as cKrox-
infected cells (GFP+). Thus, cKrox represses the expression 
of three distinct CD8 lineage markers, namely the CD8 
  coreceptor itself, cytotoxic genes such as perforin and gran-
zyme B, and the cytokine IFN-γ.
Figure 1.  cKrox inhibits CD8 transcription in mature CD8 T cells. 
(A) CD4-depleted splenocytes transduced with either control (left) or 
cKrox (right) supernatants were analyzed for GFP and for CD4 and CD8 
surface expression by fl  ow cytometry. Two parameter dot plots gated on 
all live cells are shown. The mean fl  uorescence intensity of CD8 staining 
was 3,735 in control- and 867 in cKrox-transduced cells. Results are rep-
resentative of more than fi  ve experiments. (B) T cells from E8(I)-hCD2 
reporter mice were transduced with either control or cKrox retrovirus and 
analyzed by fl  ow cytometry for GFP, hCD2, CD4, and CD8 expression. 
Two parameter dot plots gated on CD8+ cells are shown. Results are rep-
resentative of three experiments performed on three distinct founder-
derived lines, all with CD8-specifi  c hCD2 expression.JEM VOL. 204, February 19, 2007  269
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cKrox inhibits the expression of a key regulator 
of CD8 differentiation
The inhibition by cKrox of IFN-γ production was unexpected, 
as CD4 T cells can diff  erentiate into type 1 (Th1) eff  ectors 
that produce IFN-γ. Two T-box transcription factors, eome-
sodermin (Eomes) and T-bet, control T cell expression of IFN-γ 
(14–16). Both factors are expressed in CD8 T cells, whereas 
T-bet is primarily responsible for Th1 CD4 T cell commit-
ment (17). Thus, we considered the possibility that cKrox was 
impairing IFN-γ production in CD8 T cells by repressing 
Eomes. Indeed, cKrox transduction in CD8 T cells reduced 
Eomes mRNA levels to <25% of those in control-transduced 
cells but had essentially no eff  ect on T-bet expression (Fig. 3 A). 
Furthermore, cKrox transduction reduced expression of 
IL-2Rβ (CD122), a target of Eomes in CD8 T cells (18) 
(Fig. 3 B). In contrast, cKrox did not aff  ect expression of 
IL-7Rα (CD127), a receptor normally expressed on both 
CD4 and CD8 T cells (Fig. 3 B).
These fi   ndings supported the hypothesis that cKrox 
impairs IFN-γ production by reducing Eomes expression. 
If that were the case, enforced coexpression of Eomes with 
cKrox should restore IFN-γ production to levels normally 
observed in CD8 T cells. To evaluate this prediction, 
we cotransduced CD8 T cells with retroviruses encoding 
cKrox–internal ribosome entry site (IRES)-GFP or an Eomes-
IRES–nerve growth factor receptor (NGFR) cassette (19). 
Cell infection with this virus was detected through surface 
expression of the truncated NGFR protein (Fig. S4 A, available 
at http://www.jem.org/cgi/content/full/jem.20061982/DC1) 
and resulted in a modest increase in Eomes expression 
  compared with nontransduced cells (Fig. S4 B). Cells coin-
fected by both Eomes and cKrox viruses had greater expression 
of IFN-γ than cells infected with cKrox alone (Fig. 3 C). This 
supported the conclusion that cKrox impairs IFN-γ produc-
tion in part by reducing Eomes expression. However, IFN-γ 
production by Eomes-cKrox–coinfected cells did not reach 
levels observed in uninfected or Eomes-only–infected cells. 
This suggested that additional mechanisms, independent from 
or downstream of Eomes, contributed to the repression by 
cKrox of IFN-γ or cytotoxic genes. Supporting this possibility, 
cotransduction of Eomes did not prevent the repression of per-
forin by cKrox (Fig. 3 D). We conclude from these experi-
ments that cKrox inhibits cytotoxic gene expression both by 
repressing Eomes expression and through additional mecha-
nisms that circumvent the functional redundancy between 
Eomes and T-bet.
Unlike disruption of T-bet and Eomes function (18), 
cKrox expression represses CD8, implying that the spectrum 
of cKrox targets extends beyond that of Eomes. As cKrox 
belongs to a family of proteins that generally act as transcrip-
tional repressors, it is possible that it represses CD8 or eff  ector 
genes directly by binding to their cis-regulatory elements. 
Another nonmutually exclusive possibility is that cKrox im-
pairs the expression or function of a so far unknown regulator 
of CD8 diff  erentiation that would act upstream of T-box pro-
teins and thereby control the expression of CD8 and Eomes.
Figure 2.  cKrox represses cytotoxic effector gene expression and 
function in CD8 T cells. (A) Expression of perforin, granzyme B (Gran B), 
and IFN-γ genes was analyzed by RT-PCR in sorted GFP+ CD8 T cells 3 d 
after transduction with control or cKrox retrovirus. Results are presented 
relative to gene expression in control-transduced cells (arbitrarily set to 
100 for each gene). (B) Analyses of granzyme B protein expression by 
intracellular staining and fl  ow cytometry are depicted by overlaid histo-
grams showing staining of cKrox- or control-transduced CD8+ T cells or 
of control-transduced CD4 T cells. (C) cKrox impairs CD8 cell cytotoxicity. 
P14 TCR T cells transduced with either control or cKrox retroviruses were 
sorted for GFP expression and assessed for cytotoxicity against LCMV 
gp33-loaded EL-4 targets labeled with the DiD Vybrant Dye (see Fig. S3 
for gating strategy). Graphs plot the percentage of targets lysed (7-AAD+) 
by infected (GFP+) or uninfected (GFP–) effectors against effector/target 
ratios. (D) CD4-depleted splenocytes transduced with either control (left) 
or cKrox (right) retrovirus were restimulated for 4 h by PMA and iono-
mycin, and analyzed for GFP and IFN-γ expression by intracellular cytokine 
staining and fl  ow cytometry. Numbers indicate the percentage of GFP– or 
GFP+ cells that stained for intracellular IFN-γ. Results in each panel are 
representative of three or more experiments.270  PLASTICITY OF CD4-CD8 CELL DIFFERENTIATION | Jenkinson et al.
Retroviral expression of cKrox promotes helper-specifi  c 
gene expression.
As cKrox represses CD8 lineage genes, we examined if, 
conversely, it would induce helper-type gene expression. 
We fi  rst assessed its eff  ect on IL-2, a cytokine produced by 
activated CD4 T cells independently of type 1 or 2 eff  ector 
diff  erentiation (6). Intracellular cytokine staining and fl  ow 
cytometry showed that cKrox transduction into CD8 T cells 
promoted IL-2 production (Fig. 4 A). Another hallmark of 
CD4 cells is their high expression of Gata3, a transcription 
factor required for the production of type 2 cytokines such as 
IL-4 (20–22). cKrox transduction into CD8 cells cultured in 
type 2 conditions increased mRNA expression of Gata3 and 
of its target IL-4 (Fig. 4 B).
Thus, cKrox expression in CD8 T cells induces genes 
typical of helper diff  erentiation. However, cKrox-transduced 
CD8 cells had lower IL-2 expression than CD4 cells present 
in the same cultures (Fig. 4 A). Furthermore, although the 
levels of IL-4 and Gata3 mRNAs in cKrox-transduced CD8 
cells were within the range observed in control CD4 cells 
(Fig. 4 B), cKrox-transduced CD8 cells failed to produce de-
tectable IL-4 protein (not depicted). We conclude from these 
experiments that cKrox induces helper-specifi  c genes in CD8 
T cells, although it does not cause a complete conversion 
from cytotoxic to helper diff  erentiation. cKrox-mediated 
gene up-regulation does not exclude that cKrox primarily 
acts as a transcriptional repressor, as it could promote helper-
specifi  c gene expression through indirect “repression of re-
pressor” circuits. Notably, it is possible that Eomes repression 
in cKrox-transduced cells contributes to their increased ex-
pression of helper-specifi  c genes, as cotransduction of Eomes 
and cKrox failed to up-regulate Gata3 or IL-4, unlike trans-
duction of cKrox only (Fig. 4 B and not depicted). Such 
indirect gene cascades could conceivably be less responsive to 
cKrox than direct gene repression, contributing to limit the 
up-regulation of helper-specifi  c genes in cKrox-transduced 
CD8 cells.
In summary, this study identifi  es functional targets of the 
zinc fi  nger transcription factor cKrox, including the mature 
cell–specifi  c E8(I) CD8 enhancer and the key regulator of 
  cytotoxic diff  erentiation Eomes. It shows that cKrox im-
pairs cytotoxic eff  ector diff  erentiation through both Eomes-
dependent and -independent mechanisms. These observations 
demonstrate that the genetic program of CD8 cells remains 
sensitive to cKrox after these cells exit the thymus, rather than 
being locked in a confi  guration constitutively permissive to 
cytotoxic gene expression. This implies that cKrox must be 
permanently repressed in CD8 cells to maintain CD8 expres-
sion and to preserve their cytotoxic eff  ector function.
Recent findings suggest that epigenetic changes in 
DNA or chromatin structure are key to perpetuate CD4-
CD8 lineage–specifi  c gene expression in postthymic T cells 
Figure 3.  cKrox-induced Eomes repression mediates in part its 
reduction of IFN-𝗄 production. (A) cKrox represses Eomes but not 
T-bet expression. Sorted GFP+CD8+ cells were analyzed as in Fig. 2 A 
for Eomes and T-bet gene expression. (B) cKrox- or control-transduced 
CD4-depleted splenocytes were analyzed by fl  ow cytometry for CD122 and 
CD127 surface expression. Two parameter dot plots are gated on all live 
cells. Numbers represent mean fl  uorescence intensity of CD122 or CD127 
expression in GFP+ cells. Results are representative of three experiments. 
(C and D) CD4-depleted splenocytes were cotransduced with Eomes-
NGFR and cKrox-GFP viruses. 3 d later, fl  ow cytometric analysis of CD8, 
NGFR, and GFP expression distinguishes CD8 cells infected with either the 
Eomes or cKrox virus, with both viruses (both), and uninfected CD8 cells 
(none), as depicted in Fig. S4 A. (C) Analyses of IFN-γ production by intra-
cellular cytokine staining are shown as single-parameter histograms 
gated on each population. Numbers represent the percent of cells produc-
ing IFN-γ. (D) Perforin gene expression was analyzed by RT-PCR on sorted 
cells from each population and is expressed relative to uninfected cells 
(set to 1 arbitrarily). Results in each panel are representative of two 
 separate  transductions.JEM VOL. 204, February 19, 2007  271
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(1, 3, 23–25). Notably, the maintenance of CD4 silencing in 
CD8 cells may involve repositioning of unexpressed core-
ceptor loci to heterochromatin (7, 8), whereas type 2 cyto-
kine expression in CD8 cells is repressed in part by DNA 
methylation (23, 24). Although epigenetic changes at the co-
receptor or eff  ector gene level are essential to maintain lin-
eage separation, our fi  ndings demonstrate that key aspects of 
lineage-specifi  c gene expression remain under the dynamic con-
trol of transcription factors. The induction of CD4-specifi  c 
genes by cKrox shows that such plasticity is not limited to 
genes actively expressed in CD8 cells, despite the constraints 
to transcription factor access thought to be imposed by epi-
genetic changes at helper-specifi  c loci in CD8 cells (23, 24).
This study reveals a persistent plasticity in gene expression 
after the divergence of CD4 and CD8 lineages, reminiscent 
of the persistent dependence of B cell–specifi  c gene expres-
sion on Pax5, a transcription factor key to the emergence of 
the B cell lineage in hematopoietic precursors (26). Future 
experiments will assess whether cKrox disruption in mature 
CD4 T cells results in a loss of CD4 helper diff  erentiation and 
whether cKrox aff  ects epigenetic chromatin modifi  cations. 
Finally, this study provides a proof of principle that genetic 
approaches can dissociate functional diff  erentiation from 
MHC antigen specifi  city in mature T cells. Although the 
identifi  cation of cKrox targets will be required for further 
progress in this direction, our fi  ndings open new perspectives 
for disabling pathologic cytotoxic properties or endowing 
MHC I–restricted T cells with helper function.
MATERIALS AND METHODS
Cell culture and stimulation. Peripheral T cells from lymph nodes, 
spleens, or both were obtained from wild-type (C57BL/6) or E8(I) reporter 
mice, depleted of B cells using anti–mouse IgG-coated beads (Polysciences) 
or of CD4 T cells using Dynal beads, and stimulated by either 5 μg/ml of 
plastic-coated anti-CD3, 1 μg/ml of soluble anti-CD28, and 50 U/ml IL-2, 
or by 1 μg/ml of soluble anti-CD3 and 2 μg/ml anti-CD28 in the presence 
of 5 μg/ml anti–IL-12 and 5 U/ml IL-4 (Th2 conditions). E8(I) reporter 
mice (Fig. 1 B) were newly generated according to published procedures 
(27) using a previously reported construct (Tg-b) (13). P14 TCR transgenic 
mice were originally obtained from Taconic Farms. Animal procedures used 
in this study were approved by the NCI Animal Care and Use Committee.
Measurements of cytotoxic activity. P14 TCR T cells were activated 
by mitomycin C–treated H-2b splenocytes pulsed with LCMV gp 33 
(KAVYNFATC) and transduced with either cKrox or control retrovirus. 
3 d after transduction, eff  ector cells were sorted for GFP expression and 
rested overnight in the presence of 50 U/ml IL-2. EL-4 targets were loaded 
with 10−7 M gp33, labeled with DiD Vybrant dye (Invitrogen) according to 
the manufacturer’s instructions, and cocultured with rested eff  ectors at various 
eff  ector/target ratios. Cell death was assessed by fl  ow cytometry after the 
addition of 1 mg/l 7-AAD and is expressed as a percentage of 7-AAD+ 
events among DiD+ GFP– cells (Fig. S3). Assessments of CD107a external-
ization are described in the legend to Fig. S2.
Gene and protein expression analyses. Cells were stained 3 d after re-
troviral transduction using published procedures (11). Cytokine staining was 
performed after a 4-h PMA-ionomycin restimulation using the Cytofi  x/
Cytoperm kit (Becton Dickinson). Cell fl  uorescence was measured on 
either a two-laser FACSCalibur or an LSRII (both from BD Biosciences). 
Antibodies were from Caltag or BD Biosciences.
For RT-PCR analyses, cells were sorted with a FACSVantage (BD 
Biosciences), and RNA was extracted with Trizol (Invitrogen) and reverse-
transcribed with random hexamers. An ABI PRISM 7900HT sequence de-
tection system (Applied Biosystems) was used for quantitative real-time 
PCR according to the manufacturer’s instructions using previously pub-
lished primer and probe sets (18). Gene expression values are normalized to 
HPRT in the same sample. Analyses of cKrox protein expression in trans-
duced cells were performed as described previously (11).
Retrovirus construction and transduction. A pMRX-based bicistronic 
retrovirus (28) expressing cKrox upstream of an IRES and GFP was con-
structed and transfected into packaging cells (29) to produce retroviral super-
natants (detailed procedures available on request). 1 d after activation, cells 
were resuspended in 1 ml of retroviral supernatant containing 20 μg poly-
brene (Chemicon International), centrifuged at 6,000 g for 90 min at 25°C, 
and placed into fresh media containing the same cytokines as used in the 
  initial stimulation.
Online supplemental material. Fig. S1 shows a schematic of the control 
and cKrox retroviruses and expression levels of cKrox in retrovirus-
  transduced cells as analyzed by immunoprecipitation and immunoblotting. 
Fig. S2 shows the reduced externalization of the cytotoxic granule mem-
brane protein CD107a in cKrox-transduced CD8 T cells compared with 
control-transduced cells. Fig. S3 depicts the gating strategy used for fl  ow 
cytometry–based cytotoxicity assays shown in Fig. 2 C. Fig. S4 A shows the 
fl  ow cytometric gating and sorting of cells cotransduced with the cKrox 
Figure 4.  cKrox promotes expression of helper-specifi  c genes by 
CD8 T cells. (A) Lymph node cells transduced with cKrox or control retro-
virus were analyzed by intracellular staining and fl  ow cytometry for IL-2 
production. Overlaid histograms gated on CD8+GFP+ (left) or CD4+GFP+ 
(right) cells show IL-2 expression after restimulation with PMA and iono-
mycin (fi  lled) or without restimulation (dotted line). (B) mRNA expression 
of Gata3 and IL-4 was analyzed by RT-PCR in cKrox- or control-transduced 
CD8 cells and in untransduced CD4 cells, all activated in type 2 conditions. 
Results are relative to control-transduced CD8 cells (arbitrarily set to 1). 
Results in each panel are representative of three experiments.272  PLASTICITY OF CD4-CD8 CELL DIFFERENTIATION | Jenkinson et al.
(GFP) and Eomes (NGFR) retroviruses analyzed in Fig. 3 (C and D). Fig. S4 B 
compares the expression of endogenous Eomes mRNA in uninfected 
CD8 T cells and in CD8 T cells expressing retrovirally transduced Eomes, 
cKrox, or both. Figs. S1–S4 are available at http://www.jem.org/cgi/
content/full/jem.20061982/DC1.
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